Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2024/06/068921
CTRI/2024/06/068921
Not yet recruiting
Phase 3

A Double Blind Randomized Placebo Controlled Pilot Study Evaluating The Efficacy Of Imeglimin In Patients With Polycystic Ovarian Syndrome - nil

Riya Sharma self0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Riya Sharma self
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Riya Sharma self

Eligibility Criteria

Inclusion Criteria

  • •Polycystic ovarian syndrome diagnosed patient with BMI \= 25 kg/m2
  • •\-Patients willing to give informed consent.

Exclusion Criteria

  • •\-History of allergic reactions attributed to compounds of similar chemical or biologic composition of metformin or imeglimin
  • •\-Patients with history renal dysfunction (documented in biochemical test), acute / chronic metabolic acidosis, congestive cardiac failure needing drug treatment, lactic acidosis
  • •\-Patients on drug known to have significant drug\-drug interactions either metformin or imeglimin
  • •\-Pregnant females

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Immunoglobulin therapy in Lung TransplantTransplantationRespiratory - Other respiratory disorders / diseases
ACTRN12618001394235The Alfred Hospital40
Active, not recruiting
Phase 1
Trial of oxytocin for the treatment of emotional withdrawal symptoms and for relapse prevention in abstinent heroin dependent individualsOpioid dependence. The study will be investigating the efficacy of Syntocinon (oxytocin) on treating the withdrawal symptoms and cravings that opioid (e.g. almost always heroin) dependent individuals experience following detoxification.MedDRA version: 20.0 Level: LLT Classification code 10057379 Term: Addiction relapse System Organ Class: 100000004873MedDRA version: 20.0 Level: LLT Classification code 10001126 Term: Addiction any drug System Organ Class: 100000004873Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
EUCTR2014-002708-26-GBniversity of Surrey3
Not yet recruiting
Phase 3
The Myer Foundation Study into Multiple SclerosisRelapsing remitting multiple sclerosisNeurological - Multiple sclerosis
ACTRN12606000359538Melbourne Health20
Completed
Not Applicable
A pilot study of D-cycloserine-augmented cognitive behavioural therapy (CBT) with exposure therapy in adolescents with obsessive-compulsive disorder (OCD)Obsessive-compulsive disorderMental and Behavioural Disorders
ISRCTN70977225Institute of Psychiatry, Kings College London (UK)24
Active, not recruiting
Phase 1
A randomised double-blind placebo-controlled pilot study of D-cycloserine-augmented exposure therapy in adolescents with obsessive-compulsive disorder
EUCTR2008-006947-38-GBKing's College London (Institute of Pyschiatry)24